CRMD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

8.140

Open

7.750

VWAP

8.00

Vol

3.00M

Mkt Cap

629.00M

Low

7.750

Amount

23.00M

EV/EBITDA(TTM)

6.00

Total Shares

79.00M

EV

701.00M

EV/OCF(TTM)

9.00

P/S(TTM)

3.00

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Show More

Events Timeline

(ET)

2026-01-08

16:30:00

Major Averages Mixed as Oil Prices Surge Nearly 4%

2026-01-08

12:00:00

Major Averages Mixed Near Noon as Investors Reassess 2026 Optimism

2026-01-08

08:20:00

CorMedix Appoints Mike Seckler as EVP & Chief Commercial Officer

2026-01-08

08:20:00

CorMedix Appoints New Board Chairman and Extends CEO Contract

2026-01-08

08:20:00

CorMedix Introduces FY 2026 Revenue Guidance of $300M to $320M

2026-01-08

08:10:00

CorMedix Announces Preliminary Financial Results for FY 2025 with Net Revenue of Approximately $310M

2025-12-18 (ET)

2025-12-18

08:10:00

CorMedix Announces Interim Results for DefenCath Study

News

an image of Globenewswire

01-09Globenewswire

CorMedix to Present Corporate Overview at 44th J.P. Morgan Healthcare Conference

an image of NASDAQ.COM

01-08NASDAQ.COM

CorMedix and GM See Significant Options Trading Volume Surge

an image of Benzinga

U.S. Initial Jobless Claims Rise to 208,000, Mixed Market Reaction

an image of Benzinga

Acuity Inc. Reports 20.2% Revenue Growth in Q1 2026

an image of NASDAQ.COM

01-08NASDAQ.COM

Exelixis Collaborates with Natera for STELLAR-316 CRC Study

an image of Globenewswire

01-08Globenewswire

CorMedix Appoints New Executive, CEO Joseph Todisco Takes Chairman Role

6 Analyst Rating

Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 17.00 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

14.00

Averages

17.00

High

22.00

Current: 0.000

Low

14.00

Averages

17.00

High

22.00

H.C. Wainwright

Buy

downgrade

$18 -> $13

AI Analysis

2026-01-23

Reason

H.C. Wainwright

Price Target

$18 -> $13

AI Analysis

2026-01-23

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on CorMedix to $13 from $18 and keeps a Buy rating on the shares. The firm says expectations have been reset following the updated 2026-2027 DefenCath guidance. CorMedix has entered the next phase of the story where clinical execution now matters more than commercial execution, the analyst tells investors in a research note.

RBC Capital

Outperform -> NULL

downgrade

$22 -> $13

2026-01-21

Reason

RBC Capital

Price Target

$22 -> $13

2026-01-21

downgrade

Outperform -> NULL

Reason

RBC Capital lowered the firm's price target on CorMedix to $13 from $22 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRMD

Unlock Now

Valuation Metrics

The current forward P/E ratio for CorMedix Inc (CRMD.O) is 4.34, compared to its 5-year average forward P/E of -4.66. For a more detailed relative valuation and DCF analysis to assess CorMedix Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-4.66

Current PE

4.34

Overvalued PE

36.18

Undervalued PE

-45.50

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

1.34

Current EV/EBITDA

3.78

Overvalued EV/EBITDA

8.54

Undervalued EV/EBITDA

-5.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

4104.57

Current PS

1.95

Overvalued PS

18376.97

Undervalued PS

-10167.84

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

find a stock that could rise 1000%

Intellectia · 20 candidates

Market Cap: 300.00M - 5.00BQuarter Revenue Yoy Growth: >= 40.0%Beta: HighRiskRevenue 5yr Cagr: >= 25List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

TG Therapeutics Inc

5.00B

MARA Holdings Inc

4.00B

Lucid Group Inc

4.00B

CorMedix Inc

629.00M

Real Brokerage Inc

767.00M

Procept Biorobotics Corp

2.00B

best stock under 20 dollars to invest in

Intellectia · 19 candidates

Market Cap: 500.00M - 10.00BPrice: <= $20.00Net Margin: >= 20.00Weekly Average Turnover: >= 1,000,000Pe Ttm: <= 15Annual Eps Yoy Growth: >= 40.0%

Ticker

Name

Market Cap$

Centerra Gold Inc

4.00B

Fortuna Mining Corp

3.00B

Qfin Holdings Inc

2.00B

Dynex Capital Inc

2.00B

Slide Insurance Holdings Inc

2.00B

SharpLink Gaming Inc

2.00B

List stocks with high sales growth rates.

Intellectia · 665 candidates

Quarter Revenue Yoy Growth: >= 10.0%Revenue 5yr Cagr: >= 10

Ticker

Name

Market Cap$

Vision Marine Technologies Inc

4.00M

BridgeBio Pharma Inc

15.00B

Eos Energy Enterprises Inc

6.00B

Bonk Inc

26.00M

Nuscale Power Corp

6.00B

Dominari Holdings Inc

66.00M

Whales Holding CRMD

Deep Track Capital, LP

Deerfield Management Company, L.P.

Trading Trends

People Also Watch

Frequently Asked Questions

What is CorMedix Inc (CRMD) stock price today?

The current price of CRMD is 8.02 USD — it has increased 3.48 % in the last trading day.

What is CorMedix Inc (CRMD)'s business?

CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

What is the price predicton of CRMD Stock?

Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is17.00 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is CorMedix Inc (CRMD)'s revenue for the last quarter?

CorMedix Inc revenue for the last quarter amounts to 104.00M USD, increased 810.22 % YoY.

What is CorMedix Inc (CRMD)'s earnings per share (EPS) for the last quarter?

CorMedix Inc. EPS for the last quarter amounts to 1.26 USD, decreased -2620.00 % YoY.

How many employees does CorMedix Inc (CRMD). have?

CorMedix Inc (CRMD) has 64 emplpoyees as of January 30 2026.

What is CorMedix Inc (CRMD) market cap?

Today CRMD has the market capitalization of 629.00M USD.